In a study on small cell lung cancer (SCLC) characterized by high invasiveness and a poor prognosis, researchers found that the upregulation of BCL2 expression was common and could be used as a predictor of drug sensitivity [39]. This evidence concerns the gene BCL2 and small cell lung carcinoma.